Home > Insider Trading > Filing (0001714899-24-000219)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1714899	Denali Therapeutics Inc.	DNLI	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1578200	P David Schenkein	C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-11-11	47,165	$18.00	68,661	No	4	M	Direct
Common Stock	Disposition	2024-11-11	27,129	$32.09	41,532	No	4	S	Direct
Common Stock	Disposition	2024-11-11	32,312	$32.87	9,220	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2024-11-11	47,165	$0.00	47,165	$18.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2027-12-06	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	26,232	Indirect	See footnote
Common Stock	31,232	Indirect	See footnote

Footnotes

Includes 5,967 Unvested RSUs.
The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted August 12, 2024.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $31.54 to $32.53 per share. Upon request by the Commission staff, the Issuer, or asecurity holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $32.54 to $33.28 per share. Upon request by the Commission staff, the Issuer, or asecurity holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee.
The shares are held of record by the Amy P. Schenkein 2004 Revocable Trust, for which the Reporting Person's spouse serves as a trustee.
25% of the shares subject to the option shall vest on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter.